New data boosts case for extended use of AstraZeneca heart drug

LONDON (Reuters) – AstraZeneca’s blood-thinner Brilinta cuts the risk of cardiovascular death by 29 percent in patients with a history of past heart attacks who keep taking it beyond the standard 12-month initial period, according to new clinical trial data.


Source: Reuters Health News